Foley Hoag Lawyers to Speak at BIO International Convention
May 21, 2012
Partners from Foley Hoag LLP will discuss legal and regulatory issues affecting the biotechnology and pharmaceutical industries at the 2012 BIO International Convention from June 18-21 at the Boston Convention & Exhibition Center in Boston.
Tuesday, June 19, 3:45-5 p.m.
Licensing Back to the Future: Understanding Option Licenses to Advance Developments Today While Preserving Rights Tomorrow
Business Development Track – Room 206AB
With increasing R&D costs, difficulty accessing capital and a diminishing pharma pipeline, collaboration deals with an option to license are understandably all the rage. This deal structure allows emerging companies to collaborate early with a strategic partner and obtain scarce development dollars, while the partner has the opportunity to lock up novel technology at an early stage of valuation. While such deals are an effective way to monetize a company’s assets in lean times, considerable risks persist if not structured properly. Led by a leading licensing attorney, a panel of seasoned business development executives explain the reasons for this trend, the differences among options, rights of first offer or negotiation, and advise companies about best practices for retaining their core technology and commercializing future inventions.
Speaker: Hemmie Chang
Thursday, June 21, 2012
Disease Foundation-Funded Drug Development Partnerships: Structuring for Success
Business Development Track - Room: 206AB
Funding from disease foundations for U.S. biomedical research has tripled over the past decade. By contributing funds, disease foundations seek to speed up the drug discovery and approval process. Although foundations contribute a portion of the costs, pharma and biotech companies, government agencies and research institutions are also contributors and have interests in how research and development will be conducted and the ultimate drug commercialized. As the number of seats at the table increase, so do the number of legal agreements and potential for conflicts. This panel will highlight the various parties particular interests (including governance structure, data sharing, IP ownership, royalties or equity, interruption licenses, indemnification) and issues that may arise with the goal of suggesting best practices for structuring these arrangements to facilitate drug development and avoid conflict.
Speaker: Beth Arnold
Foley Hoag, which is a sponsor of the 2012 BIO International Convention, also is a co-sponsor of the Business Development session track. Attendees at the BIO International Convention, the largest global event for the biotechnology industry, may visit the Foley Hoag booth (Booth #1818) to get the latest information on the firm’s diverse services and practices.
Foley Hoag also is hosting a cocktail reception for guests at Legal Harborside at Liberty Wharf, on June 19 at 6 p.m.
About Foley Hoag LLP
Foley Hoag is a dynamic law firm that represents public and private clients in a wide range of disputes and transactions worldwide. We have expertise in industries such as life sciences and healthcare, technology, energy and cleantech, investment management, and professional services. We also offer our clients market-leading international litigation and arbitration and corporate social responsibility services. From our offices in Boston, Washington, D.C. and Paris, and our Emerging Enterprise Center in Waltham, Massachusetts, we provide strategic legal advice that is tailored to each of our client’s unique goals. Foley Hoag combines powerful regional, national and international practices that share a common emphasis on client service. We are focused on what we do best: helping our clients succeed through the delivery of exceptional legal service. For more information, visit www.foleyhoag.com